Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
Amat-Santos IJ, Sánchez-Luna JP, Abu-Assi E, Melendo-Viu M, Cruz-Gonzalez I, Nombela-Franco L, Muñoz-Garcí AJ, Blas SG, de la Torre Hernandez JM, Romaguera R, Sánchez-Recalde Á, Diez-Gil JL, Lopez-Otero D, Gheorge L, Ibáñez B, Iñiguez-Romo A, Raposeiras-Roubín S; Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) Investigators.
Amat-Santos IJ, et al.
Eur J Heart Fail. 2022 Mar;24(3):581-588. doi: 10.1002/ejhf.2370. Epub 2021 Nov 9.
Eur J Heart Fail. 2022.
PMID: 34693613
Free article.
Clinical Trial.